Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

Genes & Development
Yimin HuaAdrian R Krainer

Abstract

Increasing survival of motor neuron 2, centromeric (SMN2) exon 7 inclusion to express more full-length SMN protein in motor neurons is a promising approach to treat spinal muscular atrophy (SMA), a genetic neurodegenerative disease. Previously, we identified a potent 2'-O-(2-methoxyethyl) (MOE) phosphorothioate-modified antisense oligonucleotide (ASO) that blocks an SMN2 intronic splicing silencer element and efficiently promotes exon 7 inclusion in transgenic mouse peripheral tissues after systemic administration. Here we address its efficacy in the spinal cord--a prerequisite for disease treatment--and its ability to rescue a mild SMA mouse model that develops tail and ear necrosis, resembling the distal tissue necrosis reported in some SMA infants. Using a micro-osmotic pump, we directly infused the ASO into a lateral cerebral ventricle in adult mice expressing a human SMN2 transgene; the ASO gave a robust and long-lasting increase in SMN2 exon 7 inclusion measured at both the mRNA and protein levels in spinal cord motor neurons. A single embryonic or neonatal intracerebroventricular ASO injection strikingly rescued the tail and ear necrosis in SMA mice. We conclude that this MOE ASO is a promising drug candidate for SMA the...Continue Reading

Associated Clinical Trials

References

Jan 1, 1992·Neuromuscular Disorders : NMD·T L Munsat, K E Davies
May 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·L WhitesellL M Neckers
Aug 1, 1997·Human Molecular Genetics·D D CoovertA H Burghes
Sep 2, 1997·Proceedings of the National Academy of Sciences of the United States of America·B SchrankM Sendtner
Dec 30, 1999·Nature Genetics·H M Hsieh-LiH Li
Apr 17, 2002·The Journal of Biological Chemistry·Hiroshi MiyajimaKazunori Imaizumi
Dec 3, 2002·Science·Livio PellizzoniGideon Dreyfuss
Jan 14, 2003·Nature Structural Biology·Luca Cartegni, Adrian R Krainer
Mar 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Leigh A SkordisFrancesco Muntoni
Sep 4, 2003·The Journal of Cell Biology·Michelle L McWhorterChristine E Beattie
Oct 23, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Richard S GearyArthur A Levin
Jan 22, 2004·Bioconjugate Chemistry·Serguei V VinogradovAlexander V Kabanov
Jul 23, 2004·Current Molecular Medicine·Stanley T Crooke
Oct 18, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Csilla MadocsaiKlemens J Hertel
Aug 1, 2006·The Journal of Clinical Investigation·Richard A SmithDon W Cleveland
Aug 18, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Honglai ZhangGary J Bassell
Sep 6, 2006·Neurobiology of Disease·Li-Kai TsaiHung Li
Apr 5, 2007·Nature Protocols·Tetsuichiro Saito
Jun 7, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Tristan H CoadyChristian L Lorson
Sep 1, 2007·Journal of Child Neurology·Barry S Russman
Sep 1, 2007·Journal of Child Neurology·Stephen J KolbGideon Dreyfuss
Sep 1, 2007·Journal of Child Neurology·Ching H WangUNKNOWN Participants of the International Conference on SMA Standard of Care
Jan 1, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Shawn BelverudMichael Schulder
Mar 29, 2008·American Journal of Human Genetics·Yimin HuaAdrian R Krainer
Jun 24, 2008·Lancet·Mitchell R Lunn, Ching H Wang
Jul 24, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Li-Kai TsaiHung Li
Jul 29, 2008·Annals of Neurology·Heather L NarverCharlotte J Sumner
Nov 18, 2008·Human Molecular Genetics·Kathrin MeyerDaniel Schümperli
Jun 19, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jason H WilliamsGordon J Lutz
Jun 23, 2009·Nature Structural & Molecular Biology·Mariano AllóAlberto R Kornblihtt
Jul 22, 2009·The Journal of Pediatrics·Alexandra prufer de Queiroz Campos AraujoKathryn J Swoboda
Jul 25, 2009·The Journal of Biological Chemistry·Walt F LimaStanley T Crooke
Dec 8, 2009·Biochemical and Biophysical Research Communications·Rocky G GogliottiChristine J Didonato
Jan 8, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Tristan H Coady, Christian L Lorson

❮ Previous
Next ❯

Citations

Apr 13, 2011·Archives of Neurology·Stephen J Kolb, John T Kissel
Mar 3, 2012·Molecules and Cells·Jianhua ZhouHaihong Shen
Feb 26, 2011·Transgenic Research·Monique A LorsonKevin D Wells
Dec 3, 2011·Current Neurology and Neuroscience Reports·Aga LeweltKathryn J Swoboda
Aug 10, 2011·Journal of Molecular Neuroscience : MN·Monir Shababi, Christian L Lorson
May 21, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Sarah L DeVos, Timothy M Miller
Aug 9, 2011·Journal of Medicinal Chemistry·Jingbo XiaoChristopher P Austin
Oct 28, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Erkan Y OsmanChristian L Lorson
Jan 5, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jiing-Kuan Yee, Ren-Jang Lin
Jun 3, 2011·Nature Biotechnology·Chaolin Zhang, Robert B Darnell
Apr 28, 2011·Nature Genetics·David R Sherman, Sebastien Gagneux
Aug 2, 2011·Nature Reviews. Drug Discovery·Francesco Muntoni, Matthew J A Wood
Jan 21, 2012·Nature Reviews. Drug Discovery·Ryszard KoleSidney Altman
Nov 6, 2012·Nature Reviews. Drug Discovery·Sophie BonnalJuan Valcárcel
Feb 7, 2013·Nature Reviews. Molecular Cell Biology·Alberto R KornblihttManuel J Muñoz
Jun 21, 2011·Proceedings of the National Academy of Sciences of the United States of America·Kian Huat LimWilliam G Fairbrother
Dec 16, 2010·The Journal of Biological Chemistry·Marilyn K ParraJohn G Conboy
Dec 21, 2012·Human Gene Therapy·Zhihua Gao, Thomas A Cooper
Apr 3, 2013·Human Gene Therapy·Paul N Porensky, Arthur H M Burghes
Jun 2, 2011·Briefings in Functional Genomics·Andrew G L Douglas, Matthew J A Wood
Dec 2, 2010·Human Molecular Genetics·Elisa DominguezMartine Barkats
Mar 25, 2011·Human Molecular Genetics·William J BowersMiguel Sena-Esteves
Jun 16, 2011·Human Molecular Genetics·Thanh T LeArthur H M Burghes
Aug 31, 2011·Human Molecular Genetics·Isabel C Lopez-MejiaJamal Tazi
Dec 22, 2011·Human Molecular Genetics·Paul N PorenskyArthur H M Burghes
Mar 1, 2012·Human Molecular Genetics·Eugenio Fernandez AlanisFranco Pagani
Jul 6, 2012·Human Molecular Genetics·Thomas W BebeeDawn S Chandler
Sep 21, 2013·Journal of the National Cancer Institute·Linda M Scott, Vivienne I Rebel
May 24, 2011·Nucleic Acids Research·Nicholas OwenIan C Eperon
Sep 29, 2011·Nucleic Acids Research·Jing LiuDavid R Corey
Nov 19, 2013·Current Opinion in Pediatrics·Priyamvada SinghBasil T Darras
Aug 4, 2010·Genes & Development·Arthur H M Burghes, Vicki L McGovern
Aug 17, 2012·Genes & Development·Kentaro SahashiAdrian R Krainer
Feb 10, 2012·Molecular Pharmacology·Elizabeth S BarrieWolfgang Sadee
Mar 4, 2011·Science Translational Medicine·Marco A PassiniSeng H Cheng
Jul 19, 2013·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Benoit B GouletRobin J Parks
Jul 26, 2011·The Journal of Clinical Investigation·Cathleen M LutzUmrao R Monani
Mar 30, 2011·Molecular Neurodegeneration·Le T HaoChristine E Beattie
Jun 29, 2011·Disease Models & Mechanisms·James N SleighKevin Talbot

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cajal Bodies & Gems

Cajal bodies or coiled bodies are dense foci of coilin protein. Gemini of Cajal bodies, or gems, are microscopically similar to Cajal bodies. It is believed that Cajal bodies play important roles in RNA processing while gems assist the Cajal bodies. Find the latest research on Cajal bodies and gems here.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Antisense Oligonucleotide Therapies: ND

Antisense oligonucleotides are synthetic DNA oligomers that hybridize to a target RNA. This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases.

Alternative splicing

Alternative splicing a regulated gene expression process that allows a single genetic sequence to code for multiple proteins. Here is that latest research.